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Abstract 
The use of bacteria has been attractive to cancer researchers as drug delivery vehicle because 
motile bacteria are able to penetrate in tumors. In particular, the combination of therapeutic 
bacteria and conventional chemotherapy leads to dramatically high anti-tumor efficay. However, 
the mechanisms of the synergy, in part, remain unclear. To aim for understanding the mechanisms 
of the synergy of the combination therapy, simultaneous delivery of C. novyi-NT and 
chemotherapeutic agents in tumors is mathematically modeled from porous media approach. 
Simulated doxorubicin concentration in tumors after Doxil administration with or without 
bacteria agreed reasonably well with experimental literature. The simulated doxorubicin 
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concentration in tumors by the combination of Doxil and C. novyi-NT is over twice higher than 
that of Doxil alone, as observed in previous experimental literature. This enhanced concentration 
is because of the degradation of extracellular matrix of collagen by bacterial proteolytic activity, 
which reduced interstitial fluid pressure in tumors by increasing hydraulic conductivity of 
interstitium, and thus increases convection through vessel walls. Additionally, solid stress 
alleviation caused by collagen degradation increases vessel density by decompressing blood 
vessels. On the other hand, the simulated doxorubicin concentration in tumors for non-liposomal 
doxorubicin is not enhanced by C. novyi-NT because vascular permeability of free-doxorubicin is 
larger than Doxil, and thus, increased but relatively small convection across vessel walls is 
outweighed by the efflux due to increased interstitial flow. A strategy to further enhance this 
combination therapy is discussed with sensitivity analysis. 
 
 
1. Introduction 
With the increase in cancer incidence worldwide (1), developing more effective 
cancer treatment strategy is urgent. Chemotherapeutic agents such as anti-cancer drugs and 
drug-constraining liposomes do not penetrate in tumors effectively, and this is one of the major 
limitations of chemotherapy (2). Poor drug penetration in tumors is mainly caused by two factors: 
(i) high interstitial fluid pressure and (ii) dense extracellular matrix (ECM) of collagen. Interstitial 
fluid pressure is high in tumors because of leaky blood vessels and abnormal lymphatics in tumors 
(3). Leaky blood vessels allow larger molecules to infiltrate from vessels to tumor tissues, and 
thus, leads to high osmotic pressure in tumors. Moreover, lymphatic vessels are absent in tumors 
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(4), which increases hydrostatic pressure of tumors. Consequently, drug delivery in tumors relies 
on not convection from blood vessels to tissues but diffusion (3). Moreover, penetration of larger 
particles such as antibody or liposomes is inhibited by dense extracellular matrix (ECM) of 
collagen because collagen content of extracellular matrix of tumors is high and diffusivity of larger 
molecules such as antibody or liposomes is negatively correlated to collagen content of tumors 
(5).  
To overcome this limitation of conventional chemotherapy, the use of anaerobic bacteria has 
been attractive to cancer researchers as motile bacteria have a propelling force using their 
flagellar, and thus, are able to penetrate in avascular tumor necrotic regions (6) (7). Additionally, 
anaerobic bacteria such as Salmonella or Clostridium grow and survive in only oxygen-depleted 
hypoxic areas (8) (9). For example, Bifidobacterium longum selectively localized to and 
proliferated in rat mammary tumors after systemic application (10). Thus, tumor hypoxic regions 
provide a preferable niche for bacterial growth. These opportunities allowed the emergence of a 
field so-called Bacterial Cancer Therapy, which ranges pro-drug (9) (11) (12), drug delivery vehicle 
(13) (14), immunotherapy (15) (16), combination therapy (14) (17) (18) (19) (20). For example, 
Clostridium novyi-NT (C. novyi-NT), which is a C. novyi strain devoid of its lethal toxin, has been 
investigated for its potential because of its ability to lysis cancer cells. Intravenously injected C. 
novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed 
surrounding viable tumor cells (19) (21). Moreover, magneto-aerotactic bacteria MC-1 cells 
bearing covalently bound drug-containing nanoliposomes were injected near the tumor in severe 
combined immunodeficient beige mice and magnetically guided, up to 55% of MC-1 cells 
penetrated into hypoxic regions of HCT116 colorectal xenografts (13). Furthermore, attenuated 
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Salmonella strains were genetically constructed to synthesize a therapeutic agent intracellularly 
and periodically lyse to release the compound into tumors (14). 
Notably, therapeutic bacteria alone not only demonstrate high anti-tumor effect but the 
combination with conventional chemotherapy leads to dramatically high efficacy (14) (17) (18) 
(20) (23) (22) (24) (25) (26) (27) (28). Table 1 summarizes the previous experimental works of 
combination therapy of conventional chemotherapy and bacterial cancer therapy. For example, 
administration of C. novyi-NT spores together with conventional chemotherapeutic drugs lead to 
extensive hemorrhagic necrosis of tumors often developed within 24 h, resulting in significant 
and prolonged anti-tumor effects (17). This mechanism is considered to be because anti-cancer 
agents act on the cancer cells close to tumors while C. novyi-NT destroy cancer cells in tumor 
necrotic regions (18). The combination of Salmonella choleraesuis and anti-cancer agent, cisplatin, 
acted additively to retard tumor growth and extensively prolong the survival time of the mice 
bearing hepatomas or lung tumors (22). Additionally, the combination of both circuit-engineered 
Salmonella and 5-fluorouracil (5-FU) lead to a notable reduction of tumor activity along with a 
marked survival benefit over either therapy alone (14). Moreover, the combination therapy of S. 
typhimurium VNP20009 and endostatin, an angiogenesis inhibitor, enhanced anti-tumor effects 
by inducing greater growth inhibition (23). Furthermore, the combination of Doxil, a PEGylated 
liposomal doxorubicin, and C. novyi-NT spores resulted in complete regression of tumors in 100% 
of mice and 65% of the mice were still alive at 90 days, though neither doxorubicin nor Doxil 
resulted in prolonged therapeutic effects in the mice. Perhaps more importantly, doxorubicin 
concentration in tumors is four to five times enhanced by C. novyi-NT compared with Doxil alone 
(20). This enhanced concentration seemed to be due to liposome-disrupting ability of C. novyi-
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NT because the doxorubicin concentration was not enhanced by the combination of free-
doxorubicin and C. novyi-NT (20). In their work, however, for the mechanisms of this enhanced 
doxorubicin concentration in tumors, the possibility of enhanced extravasation from blood 
vessels was excluded because doxorubicin concentration after non-liposomal doxorubicin 
treatment was not enhanced (20). But there are several factors influencing drug extravasation 
from vessels and dependent on each drug type such as vascular permeability (drug diameter), 
binding affinity, and pharmacokinetics. Thus, the possibility of enhanced extravasation of drugs 
from blood vessels by the combination of chemotherapy and C. novyi-NT might be overlooked. 
Therefore, we aim for a mechanistic understanding of enhanced drug concentration by the 
combination of chemotherapy and bacterial cancer therapy. The objective of this work is to 
mathematically model simultaneous transport of chemotherapeutic agents and Clostridium in 
tumors. 
Mathematical modeling of delivery of Clostridium in tumors is missing in literature. Mathematical 
modeling of drug delivery in tumors has been established and well-reviewed by Jain and co-
workers (29) (30) (31) (32). Mok and coworker developed a mathematical model to describe the 
spread of herpes simplex virus from the initial injection site (34). Little has been discussed about 
the role of bacterial proteolytic activity on extracellular matrix so far. Behave and co-workers  
found that the spheroid morphology was lost and the cells were loosely packed by heat-
inactivated Clostridium sporogenes and they inhibit the proliferation of cells by the morphological 
changes caused by them in the spheroid. This suggested that heat-inactivated bacteria inhibit the 
proliferation of cells by breaking down the extracellular matrix (ECM) and destroying the cell-ECM 
interactions. It was also suggested that this could be due to the extracellular proteases of C. 
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sporogenes, one of which is collagenase, that degrade the tumor tissue (35).  
This work hypothesizes that bacterial proteolytic activity of C. novyi-NT degrades extracellular 
matrix of collagen in tumors, which increases hydraulic conductivity of interstitium and thus, 
reduces interstitial fluid pressure. Most of anaerobic bacteria such as C. novyi-NT and Salmonella 
typhimurium secrete collagenase that degrades type I, II, and III collagen (table 2). Additionally, 
hydraulic conductivity of interstitium negatively correlated with collagen or glycosaminoglycan 
(GAG) content (36) (37) (figure S1). Reduced interstitial fluid pressure in turn increases convection 
through vessel walls from blood vessel to tumor tissues, which thus increases drug concentration 
in tumors. Previous experimental work showed that collagenase treatment reduced interstitial 
fluid pressure and it increased the trans-capillary pressure gradient, inducing a 2-fold increase in 
the tumor uptake and improving the distribution of the monoclonal antibody (38). Additionally, 
solid stress, a physical force in the tumors by dense extracellular matrix of both fibril collagen and 
swelling hyaluronan, has been known to be involved in cancer therapeutic efficacy by 
compressing blood vessel in tumors (39). Decompressing blood vessels by depleting collagen 
and/or hyaluronan can improve drug delivery because it improves blood vessel perfusion or 
vessel density (39). Therefore, degradation of collagen by bacterial proteolytic activity alleviates 
solid stress of tumors, which increases vessel density and thus, increases transport of drugs across 
vasculature.  
Thus, this work specifically hypothesizes that bacterial proteolytic activity influences transport of 
chemotherapeutic agents in tumors by degrading extracellular matrix (ECM) of collagen via two-
pathways: (i) degradation of ECM of collagen increases hydraulic conductivity of interstitium, and 
thus, reduces interstitial fluid pressure, (ii) it alleviates solid stress of tumors, which increases 
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vessel density. From these two pathways, the convective transport across tumor vasculature is 
enhanced, and thus, drug delivery is enhanced. This work also hypothesizes that this enhanced 
drug delivery in tumors is dependent on size of drugs because vascular permeability of liposomal 
doxorubicin with diameter 85 nm is six times smaller than free-doxorubicin (41). To validate the 
hypotheses above, we mathematically model the simultaneous delivery of Clostridium and 
chemotherapeutic agents in tumors. The objective of this work is to mathematically model 
transports of interstitial fluid, chemotherapeutic agents, and Clostridium in tumors. Our goal is to 
understand the mechanisms of the synergetic effect of the combination of chemotherapeutic 
agents and therapeutic bacteria; the specific goals are two-fold: (i) to understand how bacterial 
proteolytic activity interacts with tumor microenvironment of extracellular matrix of collagen, 
interstitium hydraulic conductivity, interstitial fluid pressure, and solid stress, and (ii) how 
remodeled tumor microenvironment influences diffusive and convective transport across 
vascular walls and interstitial fluid flow, and thus, enhances drug delivery. 
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3. Results and discussions 
  Interstitial fluid pressure is high at the core of tumors and drops at the periphery of the 
tumors (figure 2a). These simulation results agree with experimental literature showing the high 
interstitial fluid pressure in s.c. adenocarcinoma at the center of tumors and low at the periphery 
of tumors (50). Interstitial fluid pressure in healthy liver is approximately –2.2 mmHg (51), which 
is roughly close to the simulated value in normal tissues at 2 mmHg (Fig. 1a). Interstitial fluid 
velocity, which is given by Darcy law, is approximately zero at the core of tumors but high at the 
boundary between tumor and normal tissues (black line in Fig. 1b). Both concentration of Doxil 
and free-doxorubicin in plasma decreased over time after their administrations (figure S4), but 
the concentration of Doxil decreased more slowly in plasma than free doxorubicin (figure S4). This 
long-circulating ability of Doxil is because liposomal encapsulation inhibits rapid uptake by the 
reticulo-endothelial system (RES) and reduces the rate of drug leakage. Additionally, the coating 
of liposomes with polyethylene-glycol (PEG) confers optimal protection to the vesicles from RES-
mediated clearance [52] 
Doxorubicin concentration in tumors after Doxil or doxorubicin administration increased with time, 
but in a different manner 
Simulated doxorubicin concentration in tumors after administration of Doxil or free doxorubicin 
alone agreed reasonably well with experimental literature (20) (purple line in figure 2a and blue 
line in figure 2b). Note doxorubicin concentration shown here is total amount of doxorubicin in 
tumors per volume including liposomes in interstitium and cancer cells and released doxorubicin 
in interstitium and cancer cells. After Doxil administration, doxorubicin concentration in tumors 
continued to increase, reached maximum at approximately 10 h, and declined gradually (Fig. 
9 
 
2purple line). After free-doxorubicin administration, on the other hand, doxorubicin 
concentration in tumors also increased; however, it reached maximum at approximately 3 h at 
approximately 3 μg ml–1; it declined steadily afterward (figure 2, blue line). This difference in 
tumor pharmacokinetics of doxorubicin concentration is due to pharmacokinetics in plasma. Doxil 
remains longer than free-doxorubicin (figure S4), which allows Doxil to continue to extravasate 
from blood vessels to tumors. On the other hand, free-doxorubicin disappears from plasma 
rapidly, which leads to the earlier peak of tumor concentration and decline afterward. 
To investigate what factors are more influential in determining the drug concentration in tumors, 
the volumetric solute flux of convection and diffusion across vessel walls from vessels to tissues, 
and interstitial fluid flow is analyzed (figure 3a, c). Additionally, doxorubicin concentration in 
tumors is simulated by a different combination of each factor of diffusion across vascular walls, 
convection through vessel walls, and interstitial fluid flow to investigate what factor is more 
influential in determining doxorubicin concentration in tumors (figure 6). Figure 3 shows the 
solute volumetric flux of two factors: i) convection through vessel walls with interstitial flow, and 
ii) diffusion across vasculature. Note the flux due to convection here is expressed as the net flux 
of convection through vessel walls and interstitial flow, which is calculated as following: 
   
convection through vessel walls
convection due to 
interstitial flow
1 vF fJ c uc
r


 

 
because of the following reasons: (i) most of the fluid that comes in tissues from vessel flows out 
of tissues due to interstitial flow as convection; in a steady state, in which case interstitial fluid 
pressure does not change over time, the amount of the fluid from vessels is equal to the change 
in the fluid amount in the interstitium. Additionally, solute flux due to convection is in general 
(1) 
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large, reaching over 50 μg ml–1 h–1, for example (at 1 h for Doxil), particularly at the periphery of 
tumors, and also flux due to interstitial flow is also large there at approximately –40 μg ml–1 h–1. 
On the other hand, diffusive flux across vessel walls is less than 1 μg ml–1 h–1. Thus, calculating 
convection as the net increase (or decrease) due to both convection through vessel walls and 
interstitial flow makes it easier to compare it with diffusive flux.  
Volumetric convective flux of Doxil in tumors is high at the tumor periphery because of a large 
pressure difference between capillary and interstitium (solid-line in figure 2a). Diffusive flux 
across vessel walls is high around r/R = 0.5, except tumor necrotic regions (r/R < 0.4), and it is 
almost zero at the periphery (figure 3a). This smaller diffusive flux across vascular walls at the 
tumor periphery is because of large Peclet number in this area. Following Staverman-Kedem-
Katchalsky equation (Eqn. 8), the term included in the diffusion across vascular walls, 
 exp( ) 1Pe Pe   , is smaller when Peclet number is larger, Thus, larger Peclet number, where 
convection is more dominant than diffusion (that is, tumor periphery), makes the contribution of 
diffusion smaller (purple line in figure 3b). To see what factor contributes to determining drug 
concentration in tumors, doxorubicin concentration in tumors is simulated by a different 
combination of each factor (figure 4). Simulated doxorubicin concentration in tumors due to only 
diffusion across vessel walls is larger than convection alone (figure 4a). However, including 
diffusion across vascular walls, convection through vessel walls, and interstitial flow leads to 
higher doxorubicin concentration, which is close to literature value (20) (purple line in figure 4a). 
For free-doxorubicin, on the other hand, contribution of diffusion across vascular walls to the 
transport across vascular walls is much greater than convection compared with Doxil (blue in 
figure 3c, figure 6a, c) because vascular permeability of BSA with hydrodynamic radius 2-3 nm, 
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almost as large as free-doxorubicin, is approximately six times larger than Doxil with diameter 85 
nm (41). This is also clear from the simulated doxorubicin concentration in tumors that only 
diffusion across vessel walls leads to (figure 6a, c) much larger doxorubicin concentration than 
that of convection with interstitial flow (figure 6a, c).    
 Simultaneous delivery of Clostridium and chemotherapeutic agents in tumors 
Simultaneous delivery of C. novyi-NT and Doxil in tumors is simulated to understand the 
mechanisms of enhanced doxorubicin concentration by the combination of Doxil and C. novyi-NT. 
In order to validate the simulation results obtained in this work against experimental literature 
work that C. novyi-NT was administered 16 h prior to drug administration (20), bacterial transport 
in tumors is simulated 16 h prior to drug administration, and then drug transport in tumors is also 
simulated as well as bacterial transport (figure S4). Bacterial concentration in plasma decreased 
after bacterial administration from 108 – 109 CFU ml–1 to 107 CFU ml–1 at 40 h post injection (figure 
S4). Bacterial concentration in tumors agrees reasonably well with literature (42) (53) (figure 5, 
S5). Bacterial concentration increased rapidly after bacterial administration due to extravasation 
from blood vessels and reaches at 106 CFU ml–1 order immediately after administration. It 
increased dramatically after 12 h because of bacterial growth (figure 5). The lag period, the 
duration between the introduction of bacteria and onset of exponential growth, was assumed to 
be zero because it was not available from literature (53). The relatively higher bacterial 
concentration in tumors compared with literature during 12–36 h, the exponential phase, 
indicates that the lag phase period is larger than zero. Additionally, the vascular permeability of 
Clostridium is assumed to be zero due to following reasons. Clostridium is rod-shaped with 
approximately 0.5 μm x1.5 μm. However, the pore cut-off size of colorectal tumor blood vessels, 
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which describes the functional upper limit of the size of a particle that can extravasate from the 
microvessels, is 400 – 600 nm (54) and no 800-nm microspheres were seen to extravasate from 
vessels in tumors (55). Thus, we set the vascular permeability of Clostridium novyi-NT at zero for 
simplicity (that is, no passive transport across vascular walls). The possible pathway of bacterial 
penetration in tumors is at the periphery of tumors where pressure difference is larger, and then 
entered the tissues across vascular walls due to convection, and migrated in tumors due to 
motility. Here, using the random motility coefficient of Salmonella typhimurium at 5.1 x 10–9 m2 
s–1, the mean squared displacement (MSD) of Salmonella typhimurium in tumors is calculated at 
1900 μm. We assumed that bacteria are spherical with 1 μm diameter and the bacterial migration 
is inhibited by collagen in the same manner as particles with 1000 nm diameter, following eqn. 
(20)–(22) (figure S1). Previous experimental work showed Salmonella are found in tumor necrotic 
regions and the average distance between the colonies and the functional vasculature was 750 
μm  (56). This difference in the penetration distance of bacteria from blood vessels between 
literature and our modeling is possibly explained by the recent work that revealed that, in a 
confined disordered porous medium, E. coli exhibit not run-and-tumble movement but hopping-
and-trapping motility, in which cells perform rapid, directed hops punctuated by intervals of slow, 
undirected trapping (58). Two-pore models showed the interstitial space with pore radii of 13.8 
nm and 1 μm a ratio of 9:1 (57). Thus, the most pores in tumors are inaccessible to bacteria and 
only a small amount of pores are accessible to bacteria. Consequently, Salmonella or C. novyi-NT 
probably exhibit hopping-and-trapping motion in tumors with shorter hopping lengths and longer 
trapping durations (58). It seems likely that bacteria migrated in tumor necrotic regions and 
trapped in relatively larger pores than bacteria size, and formed larger colonies due to growth. 
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This difference in bacterial motility in tumors also probably explains that the penetration rate of 
Salmonella in tumors calculated from the random motility coefficient is much faster than in vitro 
experimental literature (59). 
Simulated doxorubicin concentration in tumors for the combination of Doxil and C. novyi-NT 
agreed well with experimental literature data (20) (red-line in figure 2a). It is at least twice higher 
than that of Doxil alone (figure 2a), reaching over 10 μg g–1 (red solid-line in figure 2a). On the 
other hand, however, the combination of free-doxorubicin and C. novyi-NT does not enhance 
doxorubicin concentration in tumors compared with free-doxorubicin alone (figure 2b). The 
mechanisms of these will be discussed below. 
A mechanistic understanding of enhanced doxorubicin concentration in tumors by co-
administration of Doxil and C. novyi-NT 
Figure 6 summarizes how each factor determining drug concentration in tumors is increased or 
decreased, and thus, influences drug concentration in tumors by bacterial proteolytic activity. The 
enhanced doxorubicin concentration in tumors by the combination of Doxil and C. novyi-NT is due 
to both reduced interstitial fluid pressure and solid stress alleviation, which are caused by 
bacterial proteolysis on extracellular matrix of collagen. Since C. novyi-NT secrete collagenase that 
degrades type I, II, and III collagen (45), the collagen content of the tumor interstitium decreased 
with time by bacterial proteolysis; all the collagen of type I and III is degraded at 16 h (figure not 
shown). Following the decrease in collagen content of the interstitium, hydraulic conductivity of 
tumor interstitium increased following eqn. (8). Increased hydraulic conductivity of the 
interstitium in turn reduces interstitial fluid pressure in tumors (figure 1a), which increases 
convection through vessel walls (figure 4b). Reduced interstitial fluid pressure alone increased 
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convection through vessel walls of Doxil greatly did not enhance doxorubicin concentration in 
tumors (figure b). This is because increased hydraulic conductivity in tumor interstitium not only 
reduces interstitial fluid pressure but increases interstitial fluid velocity (eqn. 1) (figure 1b), and 
thus increases efflux from tissues due to interstitial flow. Consequently, the net volumetric flux of 
tumor tissues is not increased (Fig. 4b). On the other hand, solid stress alleviation caused by the 
degradation of extracellular matrix of collagen increases both convection and diffusion across 
vessel walls in the tumor necrotic regions by increasing vessel density (Fig. 4a-d, pink in Fig. 6Sb). 
Both reduced interstitial fluid pressure and solid stress alleviation increases convection through 
vessels in tumors (red in figure 3b), which thus increases accumulation of Doxil in tumors (Fig. 2, 
red in Fig. 6Sb).  
On the other hand, concentration of free-doxorubicin in tumors is not enhanced by C. novyi-NT, 
even though extracellular matrix of collagen is degraded by bacterial proteolytic activity (green 
solid-line in figure 2b). The simulation results are consistent with previous experimental literature 
(green dashed-line in figure 2b) (20). This is partly because of larger vascular permeability of free-
doxorubicin than Doxil (41). Larger vascular permeability of free-doxorubicin makes the diffusion 
more dominant rather than convection in determining tumor concentration (Fig. 3c, d). This trend 
can obviously be seen that simulated doxorubicin concentration in tumors by only diffusion across 
vessel walls (orange in figure 4c) is much higher than the simulated one by convection through 
vessel walls and interstitial flow (light blue in figure 4c), compared with Doxil (Fig. 4a). On the 
other hand, reduced interstitial fluid pressure due to the degradation of collagen decreases 
convection (Fig. 3d) because increased convection across vessel walls is outweighed by increased 
efflux due to increased interstitial flow as convection. This different between Doxil and 
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doxorubicin is because of the following reasons: (i) diffusion across vascular walls, not convection 
through vessel walls, is the major determinant of tumor concentration for free-doxorubicin 
delivery due to its large vascular permeability, and (ii) diffusive transport is decreased by 
increased convection through vessel walls following Staverman-Kedem-Katchalsky equation (Eqn. 
8) (figure 3c, 6Sc), (iii) increased hydraulic conductivity of interstitium increases interstitial fluid 
velocity (figure 1b), which increases efflux of doxorubicin in interstitium, which is determined by 
both convection and diffusion because of the reason of (i). Thus, reduced interstitial fluid pressure 
does not enhance the net transport across vessel walls even though convection through vessel 
walls is enhanced (figure S6d). The simulated doxorubicin concentration in tumors from reduced 
interstitial fluid pressure alone (gray line in figure 4d) is lower than that without bacteria (blue 
one in figure 6c). Solid stress alleviation increases vessel density in tumor necrotic regions and 
thus, slightly increases doxorubicin concentration in tumors (figure 4c, d, pink line in figure S6d); 
this concentration from both reduced interstitial fluid pressure and solid stress alleviation is 
almost the same as that without C. novyi-NT (figure 2b, figure S6d). 
We have also simulated the simultaneous delivery of Salmonella and 5-fluorouracil (5-FU) 
because the combination of engineered therapeutic Salmonella and 5-FU led to a prolonged 
survival rates (14). To follow their experimental procedure, bacteria and 5-FU are administered at 
day 0 simultaneously. The same parameters for the transport model are used as free-doxorubicin, 
except for pharmacokinetics in plasma and binding kinetics. Note the colorectal tumor was used 
in literature work, which makes comparing simulation results in this model with experimental 
literature results reasonable. The simulated maximum concentration of 5-FU in tumors is at 
approximately 13 μg ml–1 for both 5-FU alone and 5-FU with bacteria (figure S7). After reaching 
16 
 
the maximum, 5-FU concentration in tumors decreased rapidly for 5-FU alone, less than 5% of 
the maximum concentration at 24 h. The simulated 5-FU concentration in tumors for 5-FU alone 
agreed reasonably well with experimental literature data (figure S7). On the other hand, the 
combination of 5-FU and bacteria leads to a slower decline in tumor concentration; still more 
than 20% of its maximum remains at 24 h. However, the synergetic effect of therapeutic 
Salmonella and 5-FU is not just due to this enhanced drug delivery but also due to the fact that 
engineered Salmonella typhimurium kill cancer cells by releasing encoded anti-cancer agents in 
tumor necrotic regions, while 5-FU kills the cells close to blood vessels, as discussed previously 
(18).  
Effect of binding affinity on enhanced drug delivery by bacterial proteolytic activity 
The role of binding affinity in macromolecules transport in tumors is discussed previously (29) 
(57). Higher binding affinity allows drugs to be taken up more by cancer cells, which makes the 
interstitium concentration lower. We hypothesize that faster binding affinity leads to larger 
synergetic effect because faster z binding affinity leads to lower interstitium concentration, which 
makes the convection due to interstitial flow smaller. When drugs are administered with bacteria 
because when extracellular matrix of collagen is degraded by bacterial proteolysis, the interstitial 
fluid velocity is increased (figure 1b), thus, less interstitium concentration due to higher binding 
affinity makes the efflux of interstitial flow smaller, which thus increases drug concentration 
greater. To validate this, we simulated 5-FU delivery at different binding rates here. 
Chemotherapeutic agent of 5-FU is chosen because the binding kinetics of 5-FU is described more 
simply than doxorubicin. Delivery of 5-FU in tumors with or without bacteria is simulated at 
different binding rate, k21. Unexpectedly, faster binding affinity does not enhance the synergetic 
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effect of the combination therapy (figure S7). This is because faster binding affinity makes the 
interstitium concentration lower, which thus increases the drug concentration in tumors by 
reducing the efflux due to interstitial flow. However, in the case without bacteria, less interstitium 
concentration increases diffusion across vascular walls, thus, increases drug concentration in 
tumors. Therefore, in both case, faster binding rate leads to higher 5-FU concentration in tumors. 
Note binding affinity does not play a role for the delivery of larger particles such as liposomes, 
either, because convection through vessel walls is more dominant in the transport across blood 
vessels, rather than diffusion, (ii) convection is much enhanced by bacterial proteolytic activity 
compared with smaller molecules (figure 3d, 5d). This agrees with the previous literature that 
larger proteins can achieve similar retention to smaller ones with >100-fold weaker binding (57).  
 
We compare the mechanistic understanding obtained in this work with the combination therapy 
literature, as summarized in table 1. The combination therapy of anti-angiogenesis agents and 
therapeutic bacteria is discussed not here but in sensitivity analysis part. This understanding 
(figure 10) is, at least in part, consistent with literature (table 1). Liposomal doxorubicin with 
diameter 85 nm and trastuzumab, a monoclonal antibody with hydrodynamic radius -20 nm, 
showed high synergetic efficacy in combination of C. novyi-NT. In the combination of therapeutic 
bacteria and anti-cancer drugs with smaller diameter, some show larger synergy, while the other 
show the smaller or no synergy. It remains unclear about this reasons. It should be noted that the 
anti-tumor effect is determined not just vascular permeability, pharmacokinetics, binding affinity, 
and drug delivery but metabolisms, drug resistance, etc. More importantly, another mechanism 
for combination therapy is that anti-cancer agent acts on cancer cells in well-vascularized regions, 
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while anaerobic bacteria act on avascular tumor necrotic regions (18). It seems likely that the 
mechanisms of the combination therapy of therapeutic bacteria and chemotherapy is two-fold: 
(i) anti-cancer agents kill cancer cells in the areas close to vessels, while therapeutic bacteria kill 
cells in the areas distal from cells, (ii) delivery of chemotherapeutic agents in tumors with larger 
diameter is enhanced by bacterial proteolytic activity on extracellular matrix of collagen.  This 
study at least provides an understanding of the mechanisms underlying the combination 
therapies in previous literature and also a cue to designing an effective chemotherapeutic agent 
that can be delivered effectively by proteolytic activity of tumor-targeting bacteria.  
Simulated doxorubicin concentration in cancer cells v.s. in vivo anti-tumor efficacy in experimental 
literature  
  To analyze the effect of co-administration of C. novyi-NT on anti-cancer effect of 
Doxil and doxorubicin, the doxorubicin concentration in cancer cells is calculated from the 
simulations (figure 8). In order for Doxil to be effective, doxorubicin contained in liposomes must 
be released from Doxil. Additionally, doxorubicin in tumor tissues need to be taken up by cancer 
cells to exhibit its anti-cancer effect. The process of free-doxorubicin uptake by cancer cells after 
Doxil administration contains two pathways: (i) doxorubicin is released from liposomes in the 
interstitium, and then the released one is taken up by cancer cells, and (ii) Doxil is taken up by 
cancer cells, and then the doxorubicin contained in liposomes is released there. For free-
doxorubicin, doxorubicin in the interstitium needs to be taken up by cancer cells. The case for 
free-doxorubicin is discussed here first due to its simplicity of the process. Doxorubicin 
concentration in cancer cell for free-doxorubicin increased immediately after drug administration, 
irrespective of bacteria (figure 8c); however, it reached at its maximum at approximately 6 h, and 
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then decreased gradually. This is because doxorubicin concentration in cancer cells reaches an 
equilibrium concentration with extracellular concentration. Note the total concentration in 
tumors shown in this figure is calculated as: f f c cellc c  ; the actual extracellular (interstitium) 
concentration is higher than the value in this figure. On the other hand, for Doxil, the 
concentration of Doxil in the interstitium decreases gradually because it is taken up by cancer 
cells and it releases liposome-containing doxorubicin. Finally, doxorubicin in cancer cells 
continues to increase due to both the release from Doxil and uptake of doxorubicin in the 
interstitium by cancer cells (figure 8a). Consequently, the simulated pharmacokinetics of 
doxorubicin in cancer cells for Doxil treatment is different from free-doxorubicin. To be specific, 
since free-doxorubicin does not have a process of liposome-release, doxorubicin concentration in 
cancer cells for free-doxorubicin increases more rapidly than Doxil. However, after reaching its 
maximum, the doxorubicin in cancer cells decreases gradually because of a rapid decay in plasma 
concentration (figure S4). On the other hand, for Doxil, the doxorubicin concentration in cancer 
cells increases more slowly than free-doxorubicin (figure 8a), however, it continues to increase 
because of the long-circulating ability of Doxil in plasma (44), reaching approximately 1.5 μg ml–1 
at 120 h post-injection. The higher simulated doxorubicin concentration in cancer cells for Doxil 
than doxorubicin, at the same dose, implies that Doxil is more effective than doxorubicin on 
cancer cells, even though Doxil has a process to release encapsulated doxorubicin. By 
administrating bacteria together with Doxil, the total doxorubicin concentration in tumors is over 
twice larger with bacteria than that without bacteria (figure 8b). Thus, by the combination of 
Doxil and bacteria, doxorubicin concentration in cancer cells is over twice increased compared 
with Doxil alone, reaching at 3.5 μg ml–1 at 120 h post-injection. These simulated doxorubicin 
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concentration in cancer cells are consistent with the previous experimental literature that the 
anti-tumor effect on CT26 or HCT116 colorectal cancer by Doxil is slightly larger than free-
doxorubicin (20). More importantly, they showed that though, all mice of doxorubicin and Doxil 
treatment died by 30 days and 45 days, respectively, the combination of Doxil and C. novyi-NT 
spores resulted in complete regression of tumors in 100% of mice and 65% of the mice were still 
alive at 90 days. Our modeling results agree with these experimental results because the 
simulated doxorubicin concentration in cancer cells by Doxil with bacteria is at least twice higher 
than Doxil without bacteria (20). The simulated doxorubicin concentration in cancer cells after 
co-administration of free-doxorubicin and bacteria is almost the same as that of free-doxorubicin 
alone (Fig.8c). 100% of the mice treated with C. novyi-NT and free doxorubicin at the same dose 
died within 2 weeks, while 100% of the untreated or doxorubicin-treated mice died by 20 days or 
30 days, respectively (20). Our modeling results are at least consistent with the experimental 
results in that the combination of free-doxorubicin and C. novyi-NT does not enhance doxorubicin 
concentration in tumors nor improve chemotherapeutic efficacy. 
It is worth noting here that heat-inactivated C. noyvi-NT did not enhance the anti-tumor effect of 
Doxil (20). The reason of this is probably because heat-inactivated bacteria lose motility (60); thus, 
they are not able to penetrate in tumors. Random motility coefficient of immotile bacteria is 
approximately two or three order smaller than that of motile bacteria. The random motility 
coefficient of immotile Salmonella typhimurium in water at 4.3 x 10–13 m2 s–1 (61). The calculated 
mean squared displacement (MSD) in tumors at 16 h is 42.0 μm, without considering the effect 
of collagen inhibition on bacterial migration in tumors (that is, all tumor interstitium collagen 
assumed to be degraded). Actual distance of bacterial migration from blood vessels when 
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including collagen inhibition on immotile bacterial migration should be much smaller. It seems 
that the inhibition of collagen on movement of immotile bacteria is greater because diffusion of 
particles with larger diameter are more inhibited by extracellular matrix of collagen (figure S2). 
As a result, heat-inactivated bacteria, which is no longer motile, are not able to penetrate in 
tumors. Therefore, even though heat-inactivated bacteria keep their proteolytic activity, as 
described in previous work (35), little collagen in tumors is degraded by bacterial proteolysis due 
to their poor penetration nor drug delivery is enhanced.  
Parametric sensitivity analysis 
Parametric sensitivity analysis is carried out to investigate which factor is influential in 
determining doxorubicin concentration in tumors. Each parameter is changed +30% or –30%, for 
example, and then how much the simulated doxorubicin concentration in tumors is changed 
following the increase or decrease in each parameter is analyzed. Vascular permeability of Doxil 
in tumor vessels is sensitive in determining doxorubicin concentration in tumors without bacteria, 
though it is not as sensitive when C. novyi-NT is included (figure 9). This implicates that diffusion 
across vascular walls is dominant for Doxil alone, but when C. novyi-NT is included, not diffusion 
but convection is dominant in the transport of Doxil across vessel walls. This is also supported 
from the analysis results that doxorubicin concentration in tumors is sensitive to solvent drag 
reflection coefficient with bacteria, a determinant of convection through vessel walls, while it is 
not as sensitive for Doxil alone (Fig. 9).  On the other hand, doxorubicin concentration is sensitive 
to vascular permeability for both with and without C. novyi-NT (Fig. S10). This is consistent with 
the previous discussions about size difference between Doxil and free-doxorubicin and the factors 
determining doxorubicin concentration in tumors. Diffusivity is not sensitive at all for both Doxil 
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and doxorubicin, irrespective of addition of C. novyi-NT. Doxorubicin concentration in tumors for 
Doxil with C. novyi-NT is also sensitive to proteolysis rate and vascular density. Note that 
doxorubicin concentration in tumors does not change when proteolysis rate is increased because 
all the collagen is degraded at 16 h after bacterial injection, when Doxil or free-doxorubicin is 
administered. Dose and rate constant of pharmacokinetics in plasma affect doxorubicin 
concentration to the same extent. 
Notably, Darcy hydraulic conductivity of interstitium and Starling hydraulic conductivity of blood 
vessel walls are not sensitive for free-doxorubicin, irrespective of C. novyi-NT (Fig. S10) or Doxil 
alone. But they are much more sensitive for Doxil in combination of C. novyi-NT (figure 9). This is 
explained by a previous discussions about hydraulic conductivity and interstitial conductivity and 
interstitial fluid pressure (30). The decrease in interstitial fluid pressure by changing Darcy or 
Starling hydraulic conductivity is dependent on the factor, 
pSL VK   , where Lp is Starling 
hydraulic conductivity, K is Darcy interstitium hydraulic conductivity, S/V is surface area per 
volume (also see eqn. 6 in supporting information). When   decreases from 50 to 10, decrease 
in interstitial fluid pressure in tumors is rather small. However, when   decreases from 10 to 1, 
interstitial fluid pressure decreases greatly (30). Thus, for the administration of C. novyi-NT with 
Doxil, hydraulic conductivity of the interstitium is already decreased by bacterial proteolysis on 
collagen (eqn. 6), and thus, interstitial fluid pressure decreases greatly with the reduced vascular 
hydraulic conductivity, Lp, caused by vascular normalization by anti-angiogenesis agent of 
endostatin (62) or bevacizumab (56) (63). Thus, doxorubicin concentration in tumors is easier to 
be increased when hydraulic conductivity of interstitium or vascular walls is increased (for K) or 
decreased (for Lp). In the modeling of this study,   is at 29.3 at the initial period of treatment (or 
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without bacteria), but    decreased due to bacterial proteolysis and is at nine at 16 h post 
bacterial administration. Thus, the doxorubicin concentraton is very sensitive to hydraulic 
conductivity. These sensitivity analysis with discussions here also provides a mechanistic 
understanding of the synergetic effect of combination of Salmonella typhimurium and 
angiogenesis inhibitor, endostatin (23)  or bevacizumab (25). Treatment of bevacizumab (BEV) 
and gemicitabine (GEM) followed by S. typhimurium A1-R significantly reduced tumor weight 
compared to BEV/GEM treatment alone (25). The mechanisms of this is probably because the 
combination of Salmonella and anti-angiogenesis agents dramatically reduced interstitial fluid 
pressure because of increased hydraulic conductivity in interstitium by degradation of 
extracellular matrix of collagen by bacterial proteolysis and normalized tumor vasculature and 
reduced hydraulic conductivity of tumor vasculature by bevacizumab (33). Though this reduced 
interstitial fluid pressure in tumors needs to be validated by in vivo experiment, it increases drug 
concentration in tumors by increasing convection of drugs through vessel walls greatly.  
To summarize, a mechanistic understanding of enhanced concentration of 
chemotherapeutic agents in tumors is provided (figure 10). Simulated doxorubicin concentration 
in tumors is enhanced by the combination of Doxil and C. novyi-NT than Doxil alone due to both 
reduced interstitial fluid pressure and solid stress alleviation, caused by the degradation of 
extracellular matrix of collagen by bacterial proteolytic activity. Degradation of extracellular 
matrix of collagen increases hydraulic conductivity of interstitium, which reduces interstitial fluid 
pressure in tumors, while it leads to solid stress alleviation, which increases vessel density in 
tumor necrotic regions by decompressing blood vessels. The simulated doxorubicin concentration 
in cancer cells by the combination of Doxil and C. novyi-NT is higher than that of Doxil alone, 
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which agreed with enhanced anti-tumor efficacy by this combination in previous experimental 
literature in vivo. Chemotherapeutic agents with lower vascular permeability (larger diameter) or 
faster uptake by cancer cells have greater potential for their deliveries to be improved in 
combination with bacterial cancer therapy. Sensitivity analysis along with previous literature 
shows that the anti-angiogenesis strategy can be used to further enhance this combination 
therapy by reducing interstitial fluid pressure greatly.  
 
3. Methods 
Interstitial fluid flow, drug transport, and bacterial transport in tumors are 
mathematically modeled. Interstitial fluid flow in tumor tissues is described by Darcy’s law as: 
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The governing equation of interstitial fluid transport is obtained by following Starling’s law as 
below: 
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Hydraulic conductivity in tissues negatively correlated with collagen content and 
glycosaminoglycan in the interstitium with determination coefficient R2 of 0.86 and 0.80, 
respectively (figure S1). Thus, the Darcy hydraulic conductivity of the interstitium of the tumors 
(3) 
(4) 
(5) 
(2) 
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is described with collagen content as: 
 10 10
0 0
log ( ) 1.85log ( )c
c
cK
K c
    
The coefficient is determined from previous literature [5] (36) [65] (figure S1). 
Transport of chemotherapeutic agents in tumors 
The governing equation of transport of Doxil in tumors is described as: 
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Transport of drugs across vasculature, which is described in the term, Js, and the solute flux, Js 
[mol m–2 s–1] from blood vessels is given by Staverman-Kedem-Katchalsky equation: 
convection
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The governing equation of bacterial transport in tumors is described as: 
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Proteolysis on extracellular matrix of collagen by C. novyi-NT is included in the modeling and 
proteolysis reaction rate is expressed in Michalis-Menten kinetics as following: 
 c max c
m c
c V c
t K c


 
  
where Vmax [μg ml–1 min–1] is maximum reaction rate and Km [μg ml–1] is Michaelis constant. C. 
(6) 
(7) 
(8) 
(9) 
(10) 
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novyi-NT secrete collagenase ColG, class I, M9B family, which degrades collagen type I, II, and III 
(66). C. novyi-NT do not secrete hyaluronidase (45). 
The role of solid stress on blood vessel density is included in this model for simplicity as below:, 
since all degradable collagen of type I, II, III is degraded by bacterial proteolysis before drug 
injection, the surface area of blood vessel per volume is changed as following.  
 2000 ( 0.4)
S
r R
V
   (without bacteria) 
12000 ( 0.4)
S
r R
V
  (with bacteria) 
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Figure 1. Interstitial fluid pressure in tumors decreased by bacterial proteolytic activity because it 
increases hydraulic conductivity by degrading extracellular matrix of collagen (green and orange 
lines in a). Interstitial fluid velocity is increased by bacterial proteolytic activity because it 
degrades extracellular matrix of collagen, which increases hydraulic conductivity of interstitium 
(red line in b).  Time indicated in a shows the elapsed hours after bacterial injection.  
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Figure 2. Doxorubicin concentration in tumors of Doxil treatment is enhanced with C. novy-NT 
(red solid-line) compared with that without C. novyi-NT (purple solid-line) (a), though doxorubicin 
concentration in tumors of free-doxorubicin treatment is not enhanced by C. novyi-NT (b). Solid-
line: simulation results; dashed-line with plots: literature data (23). The literature data of Doxil 
without C. novyi-NT includes those from main article (bottom ones) and supplementary 
information (top ones). 
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Figure 3. Though bacterial proteolytic activity decreases diffusion across vascular walls (a, c), it 
enhances the net flux of convection through vessel walls and that due to interstitial flow (b, d). 
Convective transport of Doxil is relatively large (deep blue in a) compared with diffusive transport 
(b) because of its smaller vascular permeability of tumor vessels, while diffusive transport is 
dominant over convection for free-doxorubicin (c, d). 
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Figure 4. Simulated doxorubicin concentration in tumors by different combinations of each factor 
such as diffusion across vascular walls, convection through vessel walls, and interstitial flow in the 
transport of Doxil alone (a), Doxil with bacteria (b), free-doxorubicin alone (c), and free-
doxorubicin with bacteria (d). Dashed lines with plots are measured doxorubicin concentration in 
previous literature (20). 
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Figure 5. Simulated bacterial concentration in tumors reaches 106 – 107 CFU ml–1 immediately 
after bacterial injection (orange line) due to extravasation from vessels and continued to increase 
gradually. It increases rapidly after 12 h due to bacterial growth, reaching over 109 CFU ml–1. Solid-
line: simulation results; dashed-line: literature (green: (53); blue: (42)). Gray dotted-line: 
simulation results without bacterial growth. Bacterial concentration is shown in logarithmic scale. 
Shrinkage of this figure is shown in supporting information. 
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Figure 6. Bacterial proteolysis on collagen influences delivery of chemotherapeutic agents in 
tumors via two pathways: (a) reduced interstitial fluid pressure by collagen degradation increases 
convection through vessel walls, decreases diffusion across vascular walls, and increases 
interstitial fluid flow, (b) solid stress alleviation of tumors increases both convection through 
vessel walls and diffusion across vascular walls. The net increase in solute flux of these transports 
leads to increased drug delivery, though net decrease leads to decreased drug delivery. 
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Figure 8.  Simulated concentration of all doxorubicin in tumors (black), Doxil in interstitium (green), 
Doxil in cancer cells (orange), doxorubicin in the interstitium (gray), and in cancer cells (red) for 
Doxil without bacteria (a), Doxil with bacteria (b), free-doxorubicin without bacteria (c), and free-
doxorubicin with bacteria (d). Dashed-line in black is measured doxorubicin concentration in vivo 
in literature (20). Note the literature data in (a) includes both data in main article and supporting 
information (20). dox: free-doxorubicin. The figure of b with enlarged vertical scale is in 
supporting information. 
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Figure 9. Darcy and Starling’s hydraulic conductivity are not sensitive to determining doxorubicin 
concentration in tumors for Doxil alone but very sensitive for Doxil with bacteria. Parametric 
sensitivity analysis for determining drug concentration in tumors at 12 h of Doxil alone (a), Doxil 
with C. novyi-NT (b). 
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Figure 10. A summary of a mechanistic understanding provided in this work. Degradation of 
extracellular matrix of collagen by bacterial proteolysis increases convection of Doxil through 
vessel walls by reduced interstitial fluid pressure and solid stress alleviation (a, b), though it does 
not enhance doxorubicin concentration for free-doxorubicin treatment (c, d) because larger 
vascular permeability of free-doxorubicin allows diffusion more dominant rather than convection 
and increased hydraulic conductivity increases interstitial fluid velocity, and thus, increases efflux 
of drugs from tissues.  
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Table 1. List of previous experimental work of combination of chemotherapy and bacterial cancer therapy 
 
 
Bacteria 
Genetic 
engineering 
of bacteria 
 Drug Drug type T1/2 [h] 
Protein 
binding 
Synergetic 
effect 
Cancer  
cell 
Referen
ce 
C. novyi-NT 
 
Dolstatin-10 (D-10) 
+ mytomycin C 
(MMC) 
Cytotoxic (D-10); 
MMC: anti-tumor 
antibiotic 
D-10: 
 t1/2    0.042, 
t1/2    : 1.6 ; 
MMC: 0.81  
D-10: 
95%3; 
MMC: 
24% 
Large colorectal 
cancer 
(17) 
  
Vinorelbine Anti-microtubule 21.4 89% Large colorectal 
cancer 
(18) 
  
Docetaxel Anti-microtubule 41 97% 
Kd = 10 
nmol l–1 
Small colorectal 
cancer 
(18) 
  
MAC321 Analogue of 
docetaxel 
 
 ∼95% Small colorectal 
cancer 
(18) 
  
Paclitaxel Anti-microtubule 20.2 89-98% Small colorectal 
cancer 
(18) 
  
Vinblastine Anti-microtubule 26.2 98-99% No colorectal 
cancer 
(18) 
  
Vincristine Anti-microtubule - 75% Small colorectal 
cancer 
(18) 
  
Non-lipoomal 
doxorubicin 
Interacts with DNA 
and inhibit 
macromolecule 
production 
14.2 75% No colorectal 
cancer 
(20) 
  
Liposomal 
doxorubicin (Doxil) 
PEGylated 
liposomal 
doxorubicin 
55 70% Large colorectal 
cancer  
(20) 
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Salmonella 
choleraesuis 
 cisplatin interferes with DNA 
replication 
0.44 * Large Murine 
lung 
tumor and 
hepatoma 
(22) 
Salmonella 
typhimurium 
VNP20009 
 endostatin anti-angiogenesis 
  
Large Murine 
melanoma 
(23) 
Salmonella 
typhimurium 
VNP20009 
 Cyclophosphamide 
(261 g/mol) 
Its metabolite 
phosphoramide 
mustard forms DNA 
crosslinks  
3-12 20% Large Murine 
melanoma 
(24) 
Salmonella 
typhimurium 
A1-R4 
 gemcitabine 
(GEM), 
bevacizumab (BEV) 
GEM:  replaces 
building blocks of 
nucleic acids  
BEV: anti-
angiogenesis 
0.23 (GEM) Negligi-
ble 
(GEM) 
Large Pancreatic 
cancer 
(25) 
Salmonella 
typhimurium 
A1-R 
 Trastuzumab (-148 
kDa) 
a recombinant IgG1 
   
12 days  Large HER-2-
Positive 
Cervical 
Cancer 
(26) 
Salmonella 
typhimurium 
Secrete 
Chemokine, 
Haemolysin,  
and Pro-
apoptotic 
peptide 
5-fluorouracil  inhibits DNA 
synthesis 
 
 
 
10% Large MC26 
colorectal 
metastasis 
in liver 
(14) 
Salmonella 
typhimurium 
VNP20009 
Carry 
scrambled 
shRNA or Sox2 
shRNA 
construct  
HM-3 angi-angiogenesis 
polypeptide  
  Large A549 lung 
cancer 
(27) 
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T1/2 and protein binding are obtained from Liston et al. (2017) (42). 0 
2. Aherne et al. (1995) (43) 1 
3. De Jonge et al. (2005) (44) 2 
4. Salmonella typhimurium A1-R is auxotrophic for leu and arg which attenuates bacterial growth in normal tissue but allows high 3 
tumor virulence (25) 4 
rMETase: recombinant  methionidase5 
Salmonella 
typhimurium 
A1-R 
 cisplatin and 
rMETase 
Interferes with DNA 
replication 
0.44 * Large cisplatinu
m-
resistant 
metastatic 
osteosarco
ma  
(28) 
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Table 2. List of anaerobic bacteria that have been investigated for bacterial cancer therapy 
1 –: facultative anaerobic; – –: obligate anaerobic 
2 Collagenase name, class, and family are obtained from https://www.uniprot.org/. (49) 
Bactreia (strain) Aerobic or 
anaerobic1 
Motility Collagenase Collagenase 
family, class, 
name2 
Degradabl
e collagen 
type 
Reference 
about 
collagenase 
Literature of 
combination 
therapy 
Clostridium 
novyi-NT 
– – + + M9B, class I, 
ColG 
I, II, III (45) (17) (18) (19) 
(20) 
Salmonella 
typhimurium 
(S. choleraesuis)  
–  + + U32 I (46) (14) (23) (22) 
Clostridium 
acetobutylicum 
– – + + U32 I (47) 
 
 
Clostridium 
sporegenes 
– – + + M9B, class I, 
ColG 
I, II, III, (IV) (48)  
Bifidobacterium 
longum 
– – – –     
Supporting information 
Methods 
2. Mathematical modeling 
Interstitial fluid flow, transport of chemotherapeutic agents, and bacterial 
transport in tumors are mathematically modeled. The details of these models are to be 
described here. The parameters used in the modeling will be described at the end of this 
section. 
2.1 Geometry 
Three-dimensional cylindroids consisting of tumor tissues (0 < r/R < 1) and 
normal tissues (1 < r/R < 2) are used as geometry for the modeling (figure 1a). Tumors 
consist of necrotic (0 < r/R < 0.4) and viable regions (0.4 < r/R < 1). Tumor tissues are 
considered as porous media consisting of cancer cells and extracellular space, which is filled 
with interstitial fluid and extracellular matrix. In the normal tissues, blood vessels and 
lymphatics are included, though lymphatics are not included in tumor tissues as lymphatics 
are absent in tumors (2). 
 
2.2 Interstitial fluid flow  
Interstitial fluid flow is a fluid flow in the tissues which regulates the function of 
the cells as well as morphogenesis and pathogenesis of tissues (1). In normal tissues, 
interstitial fluid flows from blood vessels to lymphatic vessels; however, in tumors, 
lymphatic vessels are lacking (2), and thus, drainage of interstitial fluid to lymphatics is 
prevented, which leads to elevated interstitial hydrostatic pressure in tumors. Moreover, 
blood vessels in tumors are leaky (3), which increases infiltration of large molecules from 
blood vessels to tumor tissues, and thus, increases osmotic colloidal pressure in tumors. 
Interstitial fluid flow in tumors is mathematically modeled following previous works (4) (5). 
(6) Interstitial fluid flow in tumor tissues is described by Darcy’s law as: 
 
p
u K
r

 

 
where u [m s–1] is flux of interstitial fluid flow, K [m2 Pa–1 s–1] is hydraulic conductivity of 
tumor tissues, p [Pa] is interstitial fluid pressure in tumor tissues, and r [mm] is a distance 
from the periphery. The unit of the flux, [m s–1], can be re-written as [m3 m–2 s–1], to 
understand its physical meaning of volumetric flow per area. From the continuous equation, 
the governing equation of interstitial fluid transport is obtained as below: 
 
2
2
Drainage toFlow from 
lymphaticblood
vesselsvessels
V L
p
K
r

   

  
where V  [s
–1] is volumetric flux of the interstitial fluid flow from blood vessels to tissues 
and L  [s
–1]  is volumetric flux of interstitial fluid flow from tissues to lymphatic vessels.  
Note L  is negative as interstitial fluid flows from tissues to lymphatics. Volumetric flux of 
the fluid source from the blood vessels is described by following Starling’s law as: 
    
net driving force
pV
V v v i
L SJ
p p
V V
         
where Jv [m3 s–1] is the influx of fluid from blood vessels, Lp [m Pa–1 s–1] is the hydraulic 
conductivity of blood vessel walls, S/V [m–1] is the surface area of blood vessels per volume, 
  [-] is osmotic reflection constant, v  and i  [Pa] are the colloidal osmotic pressure of 
(1) 
(3) 
(2) 
blood vessels and tissues, respectively. Volumetric flux of interstitial fluid to lymphatic 
vessels as sink term, L  [m s
–1], is written in the same manner as: 
  pL LLL L L L i
L SJ
p p
V V
         
where LpL [m2 Pa–1 s–1] is hydraulic conductivity of lymphatic vessel walls, SL/V [m–1] is the 
surface area of lymphatic vessels per volume, and pL [Pa] is interstitial fluid pressure in 
lymphatic vessels, L  [Pa] is osmotic reflection coefficient of lymphatic vessels, L [Pa] is 
osmotic colloidal pressure in lymphatic vessels. Since lymphatic vessels are absent in tumors 
(2), L is set to zero in tumor tissues. The governing equation of Eqns. (2) – (4) for tumor 
tissues are re-written as below: 
     
2
2
p
v v i
L Sp
p p
r KV
  

   

  
Assuming that parameters Lp, K, S/V, v  , and i  are constant, this equation can be re-
written as:  
 
2 2
'2 2
( )e
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where 
pL S
R KV

  and r’ is dimensional radius (
'r r R  ). Note LPL = 0 is assumed. The 
dimensionless parameter,   , is a measure of the ratio of interstitial to vascular resistances 
to fluid flow (4). The effective pressure, pe [mmHg], is the interstitial fluid pressure which 
would yield zero net volume flux out of vasculature and equal to:  
 ( )e v v ip p        
(4) 
(5) 
(6) 
(7) 
It has been well-known that a decrease in  leads to the decreased interstitial fluid pressure (4). 
In particular, when   decreases from 50 to 10, interstitial fluid pressure decreases to a small 
extent. However, when   decreases from 10 to 1, interstitial fluid pressure decreases 
dramatically (4).  
  
Effect of collagen content and glycosaminoglycan content on hydraulic conductivity of the 
interstitium 
The factors that determine hydraulic conductivity of the interstitium are given by 
Carman-Kozeny equation: the determinants include porosity (defined as fractional void 
volume,  ), wetted surface area per unit volume (S), and a dimensionless proportionality 
term, the Kozeny factor (G) (9). The role of collagen or glycosaminoglycan (GAG) of 
extracellular matrix in hydraulic conductivity in tissues has been well-discussed previously 
(9) (8) (7). Hydraulic conductivity of tissues negatively correlated with GAG content and 
collagen content (8). The hydraulic conductivities of the interstitium of different tissues with 
different collagen content and glycosaminoglycan content obtained from previous 
experimental literature are plotted in figure 2 (9) (8). Hydraulic conductivity in tissues 
negatively correlated with collagen content and glycosaminoglycan in the interstitium with 
determination coefficient R2 of 0.86 and 0.80, respectively (figure 2). Thus, the Darcy 
hydraulic conductivity of the interstitium of the tumors is described with GAG and collagen 
content as: 
 10 10 10
0 0 0
log ( ) log ( ) log ( )c G
c G
c cK
A B
K c c
    
(8) 
where cc [mg g–1] is collagen content of the interstitium, cG  [mg g–1] is glycosaminoglycan 
content of the interstitium, and A and B are coefficients. This equation is chosen in order to 
assure the initial hydraulic conductivity at cc = cc0 is the hydraulic conductivity of tumors 
without any degradation, K0. These coefficients are determined from the literature data 
(figure 2) using multi-linear regression as A = –0.865, B = –1.16. Thus, the hydraulic 
conductivity of tumor tissues at different collagen content and glycosaminoglycan content is 
calculated using eqn. (8). Note that eqn. (8) cannot be used to predict hydraulic conductivity 
of the interstitium of different tissues because it is dependent on other factors such as 
porosity and Kozeny factor as well as collagen and GAG content. In this work, this equation 
is used to predict the decrease in hydraulic conductivity when collagen content is decreased 
by bacterial proteolytic activity, as described below. 
 
2.3 Transport of chemotherapeutic agents in tumors 
Transport of chemotherapeutic agents in tumors is mathematically modeled by 
diffusion-advection equation with reactions that includes diffusion, interstitial fluid flow, 
and extravasation from blood vessels, release from liposomes (Doxil only), and uptake by 
cancer cells. We followed a previous work for the modeling of drug delivery (4) (6) (10) (11) 
with modifications from porous media approach, as well as including release term and Doxil 
and doxorubicin uptake by cancer cells. Cancer cell uptake term is included not just because 
it is important to evaluate the anti-cancer efficacy of chemotherapeutic agents but it affects 
diffusion across vascular walls and interstitial fluid flow. We chose PEGylated liposomal 
doxorubicin (Doxil) and non-liposomal free-doxorubicin as chemotherapeutic agent because 
the aim of this work is to understand the mechanisms of the enhanced doxorubicin 
concentration in tumors by the co-administration of Doxil and C. novyi-NT (12). Free 
doxorubicin is also chosen because drug concentration in tumors is not enhanced by the 
combination of free-doxorubicin and C. novyi-NT, in which the mechanisms are unclear. The 
governing equation of transport of Doxil in tumors is described as: 
   
effective
diffusion interstitial fluid solute flux
coefficient  velocity across vascular walls2
2
diffusion interstitial fluid flow extravasation from
blood vesse
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   
uptake rate release rate
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uptake to release from liposomes
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ls
uptake i i i
lip l rel lk c k c    
where 
ic  [mol l–1] is Doxil concentration in the interstitium, Deff [m2 s–1] is effective diffusion 
coefficient of liposomal doxorubicin in tumors, l  [-] is available volume fraction of Doxil, u 
[m s–1] is the velocity of interstitial fluid flow shown in Eq. (1), Js [mol l–1 s–1] is the solute flux 
from blood vessels to tumor tissues, uptakelipk  [s
–1] is uptake rate of liposomes by cancer cells, 
i
relk  [s
–1] is release rate of doxorubicin from liposomes in the interstitium. Transport of drugs 
across vasculature from blood vessels, which is described in solute flux of Js [mol m–2 s–1] is 
given by Staverman-Kedem-Katchalsky equation: 
convection
 through diffusion acorss vascular walls
 blood vessel walls
(1 ) ( )
exp( ) 1
s F F v v
Pe
J J c P c c
Pe
    

 
where JF [m s–1] is volumetric flux of interstitial fluid through vascular wall (given by eqn. (3)) 
convection
 through diffusion acorss vascular walls
 blood vessel walls
(1 ) ( )
exp( ) 1
s F F v v
Pe
J J c P c c
Pe
    

and cv [mol l–1] is drug concentration in blood 
vessels, P [m s–1] is vascular permeability of blood vessels for liposomal doxorubicin, 
(9) 
(10) 
 1 F   is the solvent-drag reflection coefficient. The Peclet number, the ratio of 
convection to diffusion, is given as (13): 
 ( ) (1 )p v v i fL p p
Pe
P
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  
On the other hand, concentration of Doxil in cancer cells, cc [μg ml–1], is described as 
following:  
 
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where 
cell
relk  [s
–1] is release rate of doxorubicin from liposomes in cancer cells, cell  [-] is 
volume fraction of cancer cell. The doxorubicin concentration in interstitium is expressed in: 
 
  3 1 2
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from liposomes doxorubicin uptake in cancer cells
i i
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The doxorubicin concentration in cancer cells is also described as following: 
 
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For the doxorubicin uptake kinetics by cancer cells, we followed a previous work (14). Ki [μg 
ml–1] is the inhibitory constant, k1 [ng 105 cell–1 (ug ml–1)–1], k2 [ng 105 cell–1] and k3 [h–1] are 
constant for doxorubicin uptake kinetics by cancer cells. The parameter k1 gives the ratio of 
intracellular to extracellular concentration at which the net rate of passive exchange is zero. 
The inhibitory constant is the concentration at which the intracellular uptake saturates. For 
the details of the kinetic modeling, see (14).  
(11) 
(11) 
(12) 
(13) 
Transport of free-doxorubicin in tumors is also described in the same manner, but it 
includes the term of doxorubicin uptake by cancer cells instead of liposome uptake and 
doxorubicin release from liposomes and described as: 
  2
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extravasation fromdiffusion interstitial fluid flow
doxorubicin uptake in cancer cellsblood vessels
( )
i i i
f f f ff i i cell
eff f sf f f celli
i f
c c cS
D uc J k k c k c
t r r V K c


   
           
 
 where 
i
fc  [mol l–1] is doxorubicin concentration in the interstitium, cb [mol l–1] is 
doxorubicin concentration binding to cancer cell, feffD   [m
2 s–1] is effective diffusion 
coefficient of doxorubicin in tumors, f  [-] is available volume fraction of doxorubicin. 
The doxorubicin concentration in cancer cells is also described as following: 
 
3 1 2
doxorubicin uptake in cancer cells
cell i
f c fi
f celli
i f
c c
k k c k
t K c


  
     
 
The solvent-drag reflection coefficient,  1 F , indicates the ratio of the solute flux across 
vasculature to the fluid flux.  
For the transport of 5-fluorouracil in tumors, the model is based on the free-doxorubicin 
transport shown in eqn. (14) with modifications of terms of uptake.  
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The 5-FU concentration in cancer cells is also described accordingly: 
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(14) 
(15) 
(16) 
(17) 
where k21 and k12 [s–1] is binding and dissociation constant of 5-fluorouracil on/off cancer 
cell membrane.   
 
Effect of geometric tortuosity and available volume fraction on effective diffusion coefficient 
Diffusion coefficient of liposomal doxorubicin in tumors is related to the geometric 
tortuosity and available volume fraction (porosity), and described as:  
 
eff intD D


   
where   [-] is tortuosity of tumors, Dint [m2 s–1] is diffusion coefficient of liposomal 
doxorubicin in the interstitium. The tortuosity value of solid tumors of 2 was used, which 
is the theoretical value for well-packed porous media (20).  
Effect of collagen content on diffusion coefficient of chemotherapeutic agents 
 Dense collagen of extracellular matrix is a major barrier to drug penetration in tumors. For 
example, diffusivity of IgG antibody in tumors has been reported to be inversely proportional 
to collagen content of tumors (21). Thus, the contribution of the effect of collagen content to 
effective diffusivity of chemotherapeutic agents is included in the modeling. Contribution of 
tortuosity to diffusivity of particles in tumors is divided to two factors as shown in eqn. (10): 
geometric factor (geometric resistance due to solid tissues), which was described in eqn. (15), 
and viscous factor (viscous resistance due to ECM of collagen, proteoglycan), which is to be 
discussed here.  
(18) 
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The viscous contribution is described using viscous tortuosity parameter ( )v cc  (22) as  
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2
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Here we denote viscous parameter ( )v cc  as a function of collagen content, cc. From eqn. 
(18) and (20), eqn. (19) can be re-written as follows: 
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The dependence of viscous tortuosity on collagen content was calculated from the diffusion 
coefficient of particles in collagen gel with different collagen content (20). We here consider 
the simple diffusion in one-dimensional collagen gel, so the first term of eqn. (21) is assumed 
to be one in the diffusion in collagen gel. The parameter, ( )v cc  , which describes the extent 
of inhibition of diffusion by collagen, was determined by plotting 
0effD D  against different 
collagen content (figure S2).  The diameter of Doxil is 80–85 nm, so we used the hydrodynamic 
radius of 40 nm. Diffusion coefficients under different collagen content were obtained from 
previous work (20). We calculated the diffusion coefficients with hydrodynamic radius of 40 
nm under different collagen contents from the data (20), and viscous tortuosity, ( )v cc , is 
calculated from figure S2 as,  
(19) 
(20) 
(21) 
 0.5
0 ( )v c c
D
c c
D
  
 
   
 
  
where   [ml mg–1] and   [-] are coefficients for viscous tortuosity. These coefficients are 
determined from the relationship between effective diffusion coefficient in collagen gels 
with different collagen content from previous literature (20) figure S2. For the 40 nm 
particles, which are used for the modeling of Doxil (diameter 85 nm),   = 0.10 [ml mg–1] and 
  = 1.03. Thus, the viscous contribution is calculated as: 
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Finally, the effective diffusion coefficient in tumors is calculated as: 
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To validate the model of eqn. (21), the effective diffusion coefficients of 2M-dextran, 76.2 
nm-radius liposomes, and IgG are calculated and the obtained diffusion coefficients are 
compared against the measured ones in vivo, as shown in figure S2. For the particles with 
hydrodynamic radius of 76 nm, the coefficients    and  were determined as   = 0.11 [ml 
mg–1] and   = 0.84 (20). Predicted diffusion coefficient in tumors agreed reasonably well with 
experimentally literature (21) (22) (23). Using these values with   = 0.05 and   = 1.4, the 
effective diffusion coefficient in U87 glioblastoma with collagen content of the interstitium of 
45 mg ml–1 is calculated as 2.24 x 10–13 m2 s–1. We used the diffusion coefficient of liposomal 
doxorubicin with diameter 85 nm (2.1 x 10–10 m2 s–1) for liposomes with 76 nm radius, which 
we used here for validation. The effective diffusivity in U87 tumor predicted in this model is 
2.24 x 10–13 m2 s–1, which agreed reasonably well with measured diffusion coefficient of 
(22) 
(23) 
(24) 
liposome with 76.2 nm radius in U87/Mu89 mice, 2.97 x 10–13 m2 s–1 (19). The predicted and 
measured diffusion coefficient in tumors is shown in Figure S3. Note that the measured 
diffusion coefficients of liposome and 2M-dextran for U87/Mu89 tumor and that of IgG for 
HSTS26T is smaller than predicted ones (Fig. S3). This discrepancy is due to the experimental 
fact that diffusion is more inhibited by collagen in tumors in vivo than in collagen gel even at 
the same collagen content, especially for larger collagen content (20). The collagen content 
of the interstitium of tumors are obtained from previous literature (21). 
 
2.4 Transport of Clostridium in tumors 
Transport of Clostridium in tumors is mathematically modeled in diffusion-advection 
equation with appropriate reactions. Motility (random motion of bacteria that repeat run 
and tumble), interstitial fluid flow, and extravasation from blood vessels, and bacterial 
growth term are included. Chemotactic term is not included in this modeling for simplicity 
Motility is expressed in diffusion equation using effective random motility coefficient, eff  
[m2 s–1], and interstitial flow is expressed in convection. Growth term is expressed in Baranyi 
model (24). Thus, the governing equation of bacterial transport in tumors is described as:  
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where b [CFU ml–1] is bacterial concentration in tumor interstitium, 
t
b  is available volume 
fraction of Clostridium in tumors. Tumor is considered as porous media that consist of 
interstitial space and cancer cells. Bacterial effective random motility coefficient in tumors, 
(25) 
eff , is described using porosity for bacteria (available volume fraction), 
t
b , and geometric 
tortuosity,  , and random motility coefficient in water, 0 [m
2 s–1], as (25) (26): 
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 Bacterial growth is expressed as (24): 
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Here the adjustment function, α(t), depends on q(t), which represents the physiological 
state of the cells (24): 
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The physiological state can be expressed as 
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The adjustment function, as given in Eqn. 26, can be considered a transformation of 
quantity q(t) and expressed as the same ‘readiness’ of the cells for the actual environment. 
The u(c) function is called the ‘inhibition’ function because it ensures the transition of the 
growth curve to the stationary phase: 
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A value of m = 1 was used here, corresponding to the logistic, or Pearl–Verhurst, growth 
model. The initial value of a physiological state can be calculated as a product of the lag 
parameter and maximum specific growth rate. 
(24) 
(25) 
(26) 
(28) 
(27) 
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2.5 Pharmacokinetics of Doxil, free-doxorubicin, and C. novyi-NT in plasma 
Concentration of Doxil, free-doxorubicin, and C. novyi-NT in blood vessel plasma 
is expressed in pharmacokinetics of two-compartment model (27). In two-compartment 
model, the drug concentration in plasma in blood vessels, cv [μg ml–1], and in tumors 
(periphery), cp [μg ml–1], are described as follows (27):  
Elimination from Transport Transport from 
blood vesselsfrom tumors blood vessels 
back to to tumours
blood vessels
v
v p d v p v v el v
dc
V V k c V k c V k c
dt
    
Transport from Transport from
blood vessels tumors to
to tumors blood vessels
p
p b p p d p
dc
V V k c V k c
dt
   
where cv [μg ml–1] is doxorubicin concentration in blood vessel plasma, Vv [m3] is the volume 
of blood vessels (1.46 ml in mice), Vp [m3] is the volume of the periphery (i.e. tumors), pk  
[h–1] is the rate constant for transport from the blood into the peripheral tissues, dk [h
–1] is 
the rate constant for transport from the peripheral tissue back into circulation, and elik  [h
–1] 
is elimination constant from blood vessels. These equations are re-formed and represented 
in second-order differentiation: 
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(31) 
(32) 
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(29) 
The solution for this equation is given as: 
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The first term of eqn. (22) is distribution phase and the second term is elimination phase. 
Model parameters, A, B [μg ml–1],  , and   [h–1] are dependent on drug or bacteria. Note 
the parameters A + B [μg ml–1] indicates the injected dose, and ln(2)   or ln(2)   [h–1] 
indicates the half-time for distribution or elimination phase, respectively. 
 
2.6 Bacterial proteolysis kinetics on collagen  
 Proteolysis on extracellular matrix of collagen by C. novyi-NT was included in the 
modeling and proteolysis reaction rate is expressed in zero-order kinetics as following: 
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c c V
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where Vmax [mg ml–1 min–1] is maximum reaction rate and Km [mg ml–1] is Michaelis 
constant. C. novyi-NT secrete collagenase ColG, class I, M9B family, which degrades collagen 
type I, II, and III (28). C. novyi-NT do not secrete hyaluronidase (29) because the C. novyi 
strains that secrete hyaluronidase are all type B strains (30), while C. novyi-NT is a type A 
strain.  
 
2.5 The effect of solid stress alleviation by bacterial proteolysis on collagen in drug delivery 
 Solid stress, which is a physical force that generates in the tumors by dense 
extracellular matrix of both collagen and hyaluronan, is known to be involved in cancer 
progression and therapeutic efficacy by compressing blood vessel in tumors (11). Compressed 
(34) 
(35) 
blood vessels decrease perfusion and/or vascular density, and thus, reduces drug delivery. 
Decompressing blood vessels by depleting collagen and/or hyaluronan can improve drug 
delivery because it improves blood vessel perfusion or vascular density (11). We included the 
role of solid stress alleviation in the mathematical modeling because extracellular matrix of 
collagen is degraded by bacterial proteolytic activity, which alleviates solid stress of tumors. 
For simplicity, in our modeling, the effect of solid stress alleviation on drug delivery is included 
by changing blood vessel density in necrotic areas (vessel area per volume, S/V) because of 
the following reasons. Previous modeling work showed that when solid stress reached a 
threshold value, the blood vessels collapse and vascular density decreases (66). In our work, 
since all degradable collagen of type I, II, III is degraded by bacterial proteolysis before drug 
injection, the surface area of blood vessel per volume is changed as following: 
2000 ( 0.4)
S
r R
V
   (without bacteria) 
12000 ( 0.4)
S
r R
V
  (with bacteria) 
The selection of vessel density value is described in Sec. 2.7. 
 
2.6 Initial and boundary conditions: 
2.6.1 Interstitial fluid flow 
Boundary conditions for tumor surrounded by normal tissues: 
Since the flux and pressure are equal at the boundary of tumor and normal tissues, the 
boundary conditions are as follows: 
 
T N
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where KT is the hydraulic conductivity at the periphery of tumors and KN is the hydraulic 
conductivity at the periphery of normal tissues. R- and R+ indicate the radius of R of tumors 
and that at normal tissue, respectively.  The boundary condition for the transport of Doxil or 
doxorubicin, and Clostridium is no flux at r = 0, and r = 2R. Also, at the boundary between 
tumor and normal tissues at r = R, 
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The collagen and hyaluronan content of tumor interstitium is at 9.0 mg ml–1 and 2.0 mg ml–
1, respectively, as initial condition (21). The governing equations above are solved by finite-
element method using COMSOL Multiphysics 5.0. The simulation results of concentration of 
Doxil or doxorubicin in tumors are validated against experimental literature data (12). The 
simulated bacterial concentration in tumors is validated against experimental literature (31) 
(42).  
 
2.7 Parameters chosen in this work 
Parameters used in this work are summarized in table 2. Most parameters used 
in this work are those of colorectal tumor because the simulation results are validated 
against experimentally measured drug concentration in colorectal tumor in vivo (12). 
The hydraulic conductivity of normal tissues of 4.2 x 10–10 m2 Pa–1 s–1 is used (32), which is 
larger than tumors at 2.38 x 10–11 m2 mmHg–1 s–1 (33) because of the following reasons: (i) 
tumor tissues are less porous than normal ones due to a rapid proliferation of cancer cells, 
which leads to reduced hydraulic conductivity, (ii) hydraulic conductivity is negatively 
(35) (40) 
correlated with glycosaminoglycan, as discussed above, and tumor tissue is usually rich in 
collagen content. Vascular permeability of Doxil at 4.0 x 10–10 m s–1 is used because vascular 
permeability of liposomes with diameter 90 nm is six times smaller than BSA in human 
tumor xenograft (34) and vascular permeability of BSA of LS174T in mice is at 2.4 x 10–9 m s–
1 (35). Available volume fraction for Clostridium in tumors of 0.05 is used because of the 
following reasons. Available volume fraction for 1 μm particles is not available from 
literature. Clostridium are rod-shaped and their size is 0.5 – 1.9 μm with length 3.0 – 16.9 
μm. Available volume fraction for 100 nm radius particles is 0.05 (19). For the tortuosity,
1.4   was used as described in the previous section. Random motility coefficient of 
Clostridium is unavailable from literature. Random motility coefficient of Salmonella 
typhimurium in water at 25°C is reported to be 6.0 x 10–9 m2 s–1 (36). Since random motility 
coefficient at 37°C is not available, we estimated it as following. Random motility coefficient 
of bacteria is described using individual cell properties such as swimming speed, v [μm s–1], 
tumbling frequency, p0 [s–1] and directional persistence,    [-] (37), as: 
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The index of directional persistence, d  , accounts for the angle a cell's path takes between 
adjacent runs. In three dimensions, d  is equivalent to the mean of the cosine of the run-to-
run angle. If the angle between runs is random, the mean run-to-run angle will be 90 degrees 
and d  will be equal to zero (38). Thus, we assumed the random angles for the tumbling, and 
thus, 0d   is assumed here. Random motility coefficient at 37°C is calculated using that at 
25°C from swimming speed and tumbling frequency as: 
(41) 
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The numbers denoted with subscript indicate the temperature in Celsius. Using the 
swimming speeds and tumbling frequencies at 25 and 37°C (39), random motility coefficient 
at 37°C is calculated at 5.1 x 10–9 m2 s–1, which used for the modeling. The vascular 
permeability of Clostridium is not available from literature. Clostridium is rod-shaped with 
approximately 0.5 μm x1.5 μm. However, the pore cut-off size of LS174T colorectal tumor 
blood vessels, which describes the functional upper limit of the size of a particle that can 
extravasate from the micro-vessels, is 400 – 600 nm (40) and no 800-nm microspheres were 
seen to extravasate from vessels in non-superfused tumors (412). Thus, we set the vascular 
permeability of Clostridium novyi-NT at zero for simplicity (that is, no passive transport 
across vascular walls). The growth parameters for Baranyi model are determined from 
previous experimental literature (42). The maximum growth rate, max   [h
–1], is determined 
from the logarithm of bacterial concentration when it is linear against time before inhibition 
period. Lag period is assumed to be zero because the measured bacterial concentration in 
previous literature incudes the contribution of extravasation from vessels, thus, lag period 
cannot be determined. This is discussed in results and discussions part in main article. 
Pharmacokinetics 
For pharmacokinetic of liposomal doxorubicin and free doxorubicin, model parameters were 
obtained from previous experimental work (45). The pharmacokinetic parameters were 
calculated from experimental data of literature to fit them with two-compartment model, 
following a previous work for curve fitting (43). Pharmacokinetic parameters of C. novyi-NT 
in plasma were obtained from the measured concentrations of C. novyi-NT spores in plasma 
(42) 
in CT26 tumor-bearing BALB/c mice (31) and calculated as A = 2.83 x 108 CFU ml–1, B = 1.72 x 
107 CFU ml–1   = 0.141 h–1 and   = 0.0019 h–1.  
The ratio of collagen content of type I, II, and III to total interstitial collagen  
Extracellular matrix of collagen consists of type I, II, III, and V collagen. Type IV collagen 
composes basement membrane of blood vessel. C. novyi-NT secrete collagenase ColG, class 
I, M9B family, which degrades collagen type I, II, and III (28) (47). The total interstitium 
collagen content is 9.0 mg ml–1 (21); however, the ratio of collagen type I, II, and III among 
total interstitial collagen (I, II, III, and V) in colorectal tumor is missing. In normal colon, type 
I collagen occupies 62%, type III 20%, and type V 12% (44). In tumors, the increase in 
collagen type I synthesis has been reported (48), which altered type I: type III collagen 5:1 
instead of 3:1 in colon fibroblast (46). Additionally, collagen type II ratio over type I, III, and 
Vin lung cancer is 26% (49). Thus, the collagen type ratio of interstitium in colorectal tumors 
is calculated as type I 61.9%, type II 20.6%, type III, 10.9%, and type V 6.5%. Finally, using the 
total collagen content of 9.0 mg ml–1 for LS174T colorectal tumors (21), the collagen content 
in the interstitium that can be degraded by C. novyi-NT, that is, type I, II, and III collagen, is 
8.42 mg ml–1. The collagen type V ratio of 6.5% calculated here is close to previous literature 
showing that the ratio of type V to the total type I, III, and V collagen in breast cancer is 
approximately 0.10, though type II collagen is not included, (50). 
Collagenolytic activity of C. novyi-NT 
The collagenolytic reaction rate of Clostridium is calculated as following.  
Collagenolytic activities of C. tetani culture were previously reported as follows . The 
hydroxyproline amount released after 36 h from the mixture of broth, Clostridium culture, 
and collagen solution (5 ml thioglycolate broth, 1 ml pre-gelled collagen, and 0.2 ml 
bacterial culture) is measured as 66% (52), which estimates the collagenolytic activity of 
14.8 μg ml–1 min–1. The measured collagenolytic activity of collagenase of 0.015% (30 ug in 
0.2 ml) at 88% also justifies this value with in vivo experimental results as follows. The 
exponential decay time,  [min] that was measured from the decrease in second harmonic 
generation (SHG) signal in vivo was reported to be 9.9 min, 1.2 x 102 min, and 3.7 x 103 min, 
for collagenase concentration of 10, 1.0, and 0% (no collagenase), respectively (51). The 
maximum reaction rate, Vmax, for these collagen degradations was calculated as: 
c c max
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Here we assume an exponential decay, as observed in previous work (51), and thus, the 
decay constant, k [h–1] is calculated as: 
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Here Michaelis constant, Km, was assumed to be zero because SHG signal decreased in a 
constant rate during the measured period, which means Km is small enough compared with 
the collagen content. The constant collagen content of the interstitium (cc) is assumed at 45 
mg ml–1 for Mu89 (21) for simplicity. Using these values, the maximum reaction rate, Vmax, is 
calculated as 4.53 mg ml–1 min–1 and 0.363 mg ml–1 min–1 for 10% and 1.0% collagenase, 
respectively. Note the decrease in collagen content by 0% collagenase was extracted from 
each decrease in collagen content because this decrease is considered to be due to 
background difference. Assuming the linearity of bacterial concentration to maximum 
reaction rate, the estimated maximum reaction rate in vivo for 0.015% collagenase is 6.79 μg 
(38) 
(40) 
ml–1 min–1, which is close to the estimated value above. Considering that 52% of 
hydroxyproline is released at 36 h from figure in literature (52) makes the value more 
believable. 
The effect of solid stress alleviation by bacterial proteolysis on collagen on drug delivery  
We increased the blood vessel density of whole tumors by 10% because of the following 
reasons: (i) ex vivo collagenase treatment decreased solid stress of tumors to 43%, 41%, 
11%, 29% (median 34.9%), especially at the center of tumors (67), (ii) Saridegib increased 
vessel density by approximately 10%, in which solid stress was reduced to 45% – 39% (11). 
From above, the vessel density in tumor necrotic regions (0 < r/R < 0.4) is changed from 
2000 m–1 to 12,000 m–1 after the degradation of extracellular matrix of collagen, which 
satisfies the total increase in vessel density by 10%.  
 
  
Supporting figures 
 
Figure S1. Darcy hydraulic conductivity of tissue are negatively correlated to 
glycosaminoglycan (GAG) or collagen contents of the interstitium. Data are derived from 
previous experimental literature (8) (21) (53). 
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Figure S2. Diffusion of larger particles in collagen gel is more inhibited by collagen than that 
of smaller ones. D0 [m2 s–1]: diffusivity in water; D [m2 s–1]: diffusion coefficient in collagen 
gel at 37°C. Data are calculated from diffusivity of particles in collagen gel with different 
collagen content. Symbol color indicates the type of particles: diffusivity of bacteria (1  μm 
sphere) is shown in orange, liposomes with diameter 76 nm is in red, 2M-dextran with 
radius 22 nm is in blue, and BSA with radius 3.5 nm is green. Data in circle, (20) in diamonds 
(54), in triangles are obtained from previous literature  
  
 Figure S3. Predicted diffusion coefficient of particles in tumors in this model agreed well 
with experimental literature (21) (22) (23). The symbol indicates the tumor type: circle is 
U87/Mu89, diamond is HSTS26T, and triangle is LS174T tumor.  
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 Figure S4. Doxil remains at high concentration in plasma longer than free-doxorubicin (Doxil 
red dashed-line; free-doxorubicin: Blue dotted-line). The concentration of C. noyvi-NT 
declined rapidly in the plasma (orange solid-line). The bacterial concentration is in 
logarithmic scale. 
  
 Figure S5. Bacterial concentration in tumors increases rapidly to over 106 CFU ml–1 due to 
extravasation from blood vessels, then it increases gradually. After 12 h, it increases again 
due to bacterial growth. Shrinkage of figure 7 in vertical axis. 
  
  
Figure S6. Simulated concentration of 5-fluorouracil in tumors with bacteria (dashed-line in 
blue) is almost as same as that without bacteria (orange). Gray-dashed line: literature data 
(41), blue solid-line: x10 binding rate for 5-FU with bacteria, orange solid-line: x10 binding 
rate for 5-FU alone. 
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Figure S7. Simulated concentration of all doxorubicin in tumors (light blue), Doxil in cancer 
cells (orange), doxorubicin in the interstitium (gray), and in cancer cells (red) for Doxil with 
bacteria. An enlargement in vertical axis of the figure 8b.  
 Figure S8. Parametric sensitivity analysis of free-doxorubicin without bacteria (a) and with 
bacteria (b) in determining doxorubicin concentration in tumors at 4 h. 
  
 Figure S9. A geometry of tumors and normal tissues (a). Tumor consists of necrotic (0 < r/R < 
0.4) and viable region (0.4 < r/R < 1), surrounded by normal tissues (1 < r/R < 2). Tissues are 
considered as porous media consisting of cancer or normal cells and remaining interstitium 
(b, c). Normal tissues include functional blood vessels and lymphatics (b), while blood 
vessels in tumors are leaky and compressed by solid stress and lymphatic vessels are absent 
(c). 
 
  
Table S1. Parameter list 
1 mmHg = 101.3 Pa 
Symbol
s 
Parameters Values Tumor type, 
bacterial strain, 
reference 
A, B Y-intercept of pharmacokinetics of 
Doxil and doxorubicin in plasma 
Doxil: A = 27.11 μg ml–1, 
B = 6.69 μg ml–1; 
Free doxorubicin: A = 
27.66 μg ml–1; B = 2.27 
μg ml–1 
Dose: 5 mg/kg for 
both; (45) 
Ab, Bb Y-intercept of pharmacokinetics of 
C. novyi-NT in plasma 
A = 2.83 x 108 CFU ml–1,  
B = 1.66 x 107 CFU ml–1 
 
C. noyvi-NT, CT26 
tumor-bearing 
BALB/c mice; 
Dose: 1.5 x 1010 
CFU/kg; (31) 
Afu, Bfu Y-intercept of pharmacokinetics of 
5-fluorouracil in plasma 
Doxil: A = 99.5 μg ml–1, 
 B = 1.433 μg ml–1 
 
5-fluorouracil, 
colorectal tumor-
bearing BALB/c 
mice; Dose: 100 
mg/kg.; Peters et 
al. (1993) 
b Bacterial concentration in 
interstitium 
Eqn. (25)  
ccell Concentration of Doxil in cancer cells Eqn. (11)  
ci Concentration of Doxil in 
interstitium 
Eqn. (9)  
cc Collagen content of interstitium Eqn. (30)  
cell
fc  Concentration of free-doxorubicin in 
cancer cell 
Eqn. (13), (15)  
i
fc   Concentration of free-doxorubicin in 
interstitium 
Eqn. (12), (14)  
i
fuc  Concentration of 5-FU in interstitium  Eqn. (16)  
cell
fuc  Concentration of 5-FU in cancer cells Eqn. (17)  
cc0 Total collagen content of the tumor 
interstitium 
9.0 mg ml–1 LS174T (21);  
ccV/cc0 Type V collagen ratio over total 
collagen 
6.5% (55) 
ch0 Hyaluronan content of tumor 
interstitium  
0.20 mg ml–1 LS174T; (21) 
cGAG0 Glycosaminoglycan content of 
tumors 
0.35 mg ml–1 LS174T; (21) 
D0 Diffusion coefficient of Doxil in 
water at 37°C 
2.1 x 10–10 m2 s–1 (56) 
Diffusion coefficient of free 
doxorubicin in water at 37°C 
8.83 x 10–10 m2 s– (62) 
Deff Effective diffusion coefficient Eqn. (18)–(22)  
K0 Darcy hydraulic conductivity in 
tumors 
2.38 x 10–11 m2 mmHg–1 
s–1  
LS174T colorectal 
cancer; (33) 
Darcy hydraulic conductivity in 
normal tissues 
2.5 x 10–11 m2 mmHg–1 s–
1 
(58) 
k1, k2, 
k3 
Kinetic parameters of doxorubicin 
uptake rate by cancer cells 
k1 = 0.00631 ng 105 cell–1 
(ug ml–1)–1; k2 = 0.126 ng 
105 cell–1; k3 = 1.01 h–1 
(14) 
k21, k12 Binding and dissociation constant of 
5-fluorouracil on cell membrane 
k21 = 0.2 s–1, k12 = 4.1 s–1 (59) 
i
lipk  Release constant of Doxil from 
liposomes in the interstitium 
1.77 x 10–4 min–1 4T1 breast 
cancer; (60) 
c
lipk   Release constant of Doxil from 
liposomes in cancer cell 
9.6 x 10–4 min–1 4T1 breast 
cancer; (60) 
Km Michaelis constant of proteolytic 
reaction rate 
0 See text 
_uptake lipk
 
Uptake rate of Doxil by cancer cells 1.0 x 10–5 s–1 B16F10 murine 
melanoma cell;  
(61) 
nv Number of cancer cells per volume 6 x 108 cell ml–1  
Lp Hydraulic conductivity of 
microvascular wall  
Tumors: 1.86 x 10–8 m 
mmHg–1 s–1  
(58) 
Normal tissues: 3.6 x 10–
10 m mmHg–1 s–1 
(58) 
P Vascular permeability in tumor 
vessels 
Doxil: 4.0 x 10–10 m s–1; 
 
LS174T colorectal 
cancer, (34) 
Free doxorubicin:  2.4 x 
10–9 m s–1 
LS174T colorectal 
cancer (Dorsal 
skinfold 
chamber); (35) 
Clostridium novyi-NT: 0 0 (see text) 
pV Capillary pressure  13.5 mmHg (63) 
q(t)  Physiological state of cells Eqn (27)  
r Distance from tumor core   
R Radius of tumors 4 mm  
S/V The ratio of surface area of blood 
vessels to volumes 
Tumor tissue: 20000 m–1 
(viable regions, r/R > 
0.4); 2000 m–1 (necrotic 
regions, r/R < 0.4 )  
(3) 
Normal tissue: 7000 m–1 
SL/V The ratio of surface area of 
lymphatics to volumes in normal 
tissues 
4300 m–1 (64) 
Vmax Maximum reaction rate 14.8 ug ml–1 (52) 
Vp Volume of tumors 267.9 mm3  
Vv Volume of blood vessel 1.46 ml  
 ,   Pharmacokinetic coefficient of drugs 
for distribution and elimination 
phase 
Doxil: 0.209 h–1;   = 
0.0169 h–1 
Free doxorubicin:   = 
0.778 h–1  = 0.0529 h–1 
Murine 
hepatocarcinoma 
cell (H22) , Dose: 
5 mg/kg; (45) 
 
b , b  Pharmacokinetic coefficient for 
distribution and elimination phase of 
C. noyvi-NT in plasma 
b = 0.139 h–1; b  =  
0.0119 h–1 
C. noyvi-NT, CT26 
tumor-bearing 
BALB/c mice; 
Dose: 1.5 x 1010 
CFU/kg; (31) 
fu , 
fu  
Pharmacokinetic coefficient for 
distribution and elimination phase of 
5-fluorouracil in plasma 
b = 1.79  h–1; b  =  
0.188 h–1 
5-FU, colorectal 
tumor-bearing 
BALB/c mice; 
Dose: 100 
mg/kg.; Peters et 
al. (1993) 
 t  Adjustment function of bacterial 
growth 
Eqn. (26)  
  ,    Doxil:    = 0.10 ml mg–1, 
  = 1.04; 
(20) 
Coefficient for determining diffusion 
coefficient at different collagen 
content 
 
Free doxorubicin:    = 
0.04 ml mg–1,   = 1.06; 
(62) 
Bacteria (1 μm diameter 
particle):    = 0.16 ml 
mg–1,   = 0.97; 
extrapolated 
from (20) 
   Random motility coefficient of 
Salmonella typhimurium at 37°C 
5.1 x 10–9 m2 s–1 (353) (36) (39) 
  Osmotic reflection coefficient  Tumors: 0.91; 
Normal tissues: 8.7x 10–5 
Tumors: (3) 
Normal tissues: 
(58) 
f  Solvent-drag reflection coefficient 0.83 (16) 
v   Osmotic colloidal pressure in blood 
vessels 
15.4 mmHg (65) 
i  Osmotic colloidal pressure in the 
interstitium  
Tumors: 17.3 mmHg; 
Normal tissues: 11.0 
mmHg 
Tumors: (58); 
Normal tissues: 
(65) 
L  Osmotic colloidal pressure in the 
lymphatic vessels 
Normal tissue: 11.8 
mmHg 
(65) 
   tortuosity 1.41 (20) 
   Available volume fraction  Doxil: 0.05; 
bacteria: 0.05; 
Free doxorubicin: 0.26; 
(18) 
5-fluorouracil: 0.26; 
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